Drug Profile
Research programme: immunotherapeutics - Millennium Pharmaceuticals/Shattuck Labs
Alternative Names: Agonist redirected checkpoint fusion proteins - Shuttuck Labs/Takeda; CD172a-Fc-CD40L; Checkpoint fusion proteins - Shuttuck Labs/Takeda; TIM3-Fc-OX40L; TIM3-Fc-OX40L ARC; VSIG8-Fc-OX40LLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Shattuck Labs; Takeda Oncology
- Developer Shattuck Labs
- Class Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Checkpoint kinase inhibitors; Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 21 Apr 2018 Pharmacodynamics data from a preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018 (3317330)
- 21 Apr 2018 Preclinical trials in Cancer in USA (unspecified route)